The Transition From Blastomere to Trophectoderm Biopsy: Comparing Two PGS Strategies
- Conditions
- Preimplantation Genetic ScreeningInfertility
- Registration Number
- NCT03062969
- Lead Sponsor
- Institut Universitari Dexeus
- Brief Summary
Shortly after the implementation of Comprehensive Chromosome Screening (CCS) techniques for Preimplantation Genetic Screening (PGS) came the transition in biopsy timing. Trophectoderm biopsy is meant to overcome the limitations of cleavage stage biopsy and single cell analysis.
- Detailed Description
The investigators have recently introduced this new approach and a frozen-thawed policy of euploid blastocysts is routinely performed.
This is a single centre retrospective study in patients undergoing a PGS cycle. The aim of the study is to assess the results obtained in a PGS programme after the implementation of a new biopsy timing and transfer policy. Results obtained in PGS cycles with blastocyst biopsy and frozen-thawed embryo transfer were analysed in comparison to cycles with cleavage stage biopsy and fresh blastocyst transfer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 383
- Own gametes
- PGS for: advanced maternal age, repeated implantation failure, recurrent miscarriages, severe male factor, and previous affected pregnancies
- PGS cycles with gamete donation
- Altered karyotypes
- Combined Preimplantation genetic diagnosis (PGD)+PGS cycles
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ongoing clinical pregnancy rate 20 weeks after embryo transfer Clinical pregnancy confirmed by ultrasound
- Secondary Outcome Measures
Name Time Method Number of available euploid blastocysts per cycle Up to 15 days after embryo biopsy Transferable or vitrified euploid blastocysts
Miscarriage Rate Until 20 weeks after embryo transfer Implantation Rate 6 weeks after embryo transfer Embryos implanted confirmed by ultrasound